Orabloc (Articaine Hydrochloride, Epinephrine)

Articaine hydrochloride, the active ingredient in Orabloc, is a local anesthetic (amide type) presented as a solution for dental intra‑oral administration. It provides rapid onset of numbness for a range of dental procedures and is combined with epinephrine to extend its effect. GNH USA supplies Orabloc as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Orabloc is a local anesthetic used in dental practice to achieve reversible loss of sensation in targeted oral tissues. - Restorative dentistry: provides numbness for cavity preparation and filling placement. - Oral surgery: enables pain control during extractions, implant placement, and biopsy procedures. - Periodontal therapy: facilitates patient comfort during scaling, root planing, and flap surgery.

Common Side Effects: - Transient lip or cheek numbness: temporary sensation loss that resolves as the drug wears off. - Mild taste disturbance: brief metallic or bitter taste in the mouth. - Mild headache: occasional headache during or after the procedure.

Serious or Rare Side Effects: - Allergic reaction (anaphylaxis): severe hypersensitivity requiring immediate medical attention. - Cardiovascular toxicity (arrhythmia): irregular heart rhythm due to epinephrine excess. - Methemoglobinemia (rare): reduced oxygen‑carrying capacity of blood, presenting with cyanosis.

Before using Orabloc, clinicians should consider the following precautions: - Allergy assessment: verify no known hypersensitivity to amide‑type anesthetics or epinephrine. - Cardiovascular status: use caution in patients with uncontrolled hypertension or arrhythmias. - Drug interactions: avoid concomitant use of non‑selective β‑blockers that may amplify epinephrine effects. - Pregnancy and lactation: assess risk–benefit ratio before administration. - Store at room temperature below 25°C: keep in the original container, protect from light and moisture.

When prescribing Orabloc, be aware of potential drug interactions. Major Interactions (Avoid): - Non‑selective β‑blockers: may potentiate epinephrine‑induced tachycardia. - Tricyclic antidepressants: increase risk of cardiac arrhythmia. - MAO inhibitors: risk of hypertensive crisis.

Moderate Interactions (Monitor Closely): - Antihistamines: may mask early signs of an allergic reaction. - Diuretics: may enhance epinephrine‑related blood pressure changes.